Shield Therapeutics PLC PDMR Transaction Notification (3846J)
23 Agosto 2021 - 1:00AM
UK Regulatory
TIDMSTX
RNS Number : 3846J
Shield Therapeutics PLC
23 August 2021
Shield Therapeutics plc
("Shield Therapeutics" or the "Company")
PDMR Transaction Notification
London, UK, 23 August 2021: Shield Therapeutics plc (LSE:STX), a
commercial stage pharmaceutical company with a focus on addressing
iron deficiency with its lead product Feraccru(R)/Accrufer(R)
(ferric maltol), announces that Mr Anders Lundstrom, Non-Executive
Director, acquired 10,000 Ordinary Shares in the Company on 20
August 2021 at an average price of $0.61 per share. Following the
transaction, Mr Lundstrom has a beneficial interest in 10,000
shares.
The notification below, which has been made in accordance with
the requirements of the EU Market Abuse Regulation, provides
further detail.
Notification and public disclosure of transactions by persons
discharging managerial responsibilities and persons closely
associated with them:
1. Details of the person discharging managerial responsibilities / person closely associated
a. Name Anders Lundstrom
--------------------------------- -------------------------------------------------------------
2. Reason for the notification
------------------------------------------------------------------------------------------------
a. Position/status Non-Executive Director
--------------------------------- -------------------------------------------------------------
b. Initial notification Initial
/Amendment
--------------------------------- -------------------------------------------------------------
3. Details of the issuer, emission allowance market participant, auction platform, auctioneer
or auction monitor
------------------------------------------------------------------------------------------------
a. Name Shield Therapeutics plc
--------------------------------- -------------------------------------------------------------
b. LEI 213800G74QWY15FC3W71
--------------------------------- -------------------------------------------------------------
4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date; and (iv) each place where transactions have been
conducted
------------------------------------------------------------------------------------------------
a. Description of the Ordinary shares of 1.5p each in the capital of the Company
Financial instrument, type
of instrument
Identification code
ISIN of Ordinary Shares: GB00BYV81293
--------------------------------- -------------------------------------------------------------
b. Nature of the transaction
Acquisition of Ordinary Shares
--------------------------------- -------------------------------------------------------------
c. Price(s) and volume(s) Price(s) Volume(s)
$0.61 10,000
----------
--------------------------------- -------------------------------------------------------------
Aggregated information
* Aggregated volume
10,000
d. * Price $6,100
--------------------------------- -------------------------------------------------------------
e. Date of the transaction 2021-08-20
--------------------------------- -------------------------------------------------------------
f. Place of the transaction OTCQX
--------------------------------- -------------------------------------------------------------
For further information, please contact:
Shield Therapeutics plc +44 (0) 191 511 8500
Greg Madison (CEO)
Hans-Peter Rudolf (CFO)
Peel Hunt LLP - Nominated Adviser & Joint
Broker +44 (0) 20 7148 8900
James Steel / Christopher Golden
finnCap Ltd - Joint Broker +44 (0) 20 7220 0500
Geoff Nash / Alice Lane/ George Dollemore
Walbrook PR - Financial PR & IR Adviser +44 (0) 20 7933 8780
Paul McManus / Lianne Cawthorne/ Alice or shield@walbrookpr.com
Woodings
About Shield
Shield is a commercial stage, pharmaceutical company with a
focus on addressing iron deficiency with its lead product Feraccru
(R) /Accrufer (R) (ferric maltol), a novel, stable, non-salt based
oral therapy for adults with iron deficiency with or without
anaemia.
Shield's lead product, Feraccru(R)/Accrufer(R), has been
approved for use in the United States, European Union, UK,
Switzerland and Australia and has exclusive IP rights until the
mid-2030s. The Group is currently launching Accrufer(R) in the US.
Feraccru(R) is already being commercialised in the UK and European
Union by Norgine B.V., who also have the marketing rights in
Australia and New Zealand. Shield also has an exclusive licence
agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the
development and commercialisation of Feraccru(R)/Accrufer(R) in
China, Hong Kong, Macau and Taiwan.
For more information, please visit www.shieldtherapeutics.com .
Follow Shield on Twitter @ShieldTx
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCPPUPPRUPGGRU
(END) Dow Jones Newswires
August 23, 2021 02:00 ET (06:00 GMT)
Shield Therapeutics (LSE:STX)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Shield Therapeutics (LSE:STX)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024
